Drug Interactions between azilsartan medoxomil and magnesium sulfate / potassium sulfate / sodium sulfate

Consumer information for this interaction is not currently available.

MONITOR CLOSELY: Concomitant use of angiotensin II receptor blockers (ARBs) and potassium salts may increase the risk of hyperkalemia. Inhibition of angiotensin II results in decreased aldosterone secretion, which in turn causes potassium retention. Life-threatening and fatal hyperkalemia can occur, especially when the combination is used in patients with risk factors such as renal impairment, diabetes, advanced age, severe or worsening heart failure, dehydration, and concomitant use of other agents that block the renin-angiotensin-aldosterone system or otherwise increase serum potassium levels.

MANAGEMENT: Caution and close monitoring are advised if angiotensin II receptor blockers (ARBs) must be used concurrently with potassium salts due to the risk of potentially life-threatening hyperkalemia. Some authorities advise against combining certain ARBs with potassium salts unless the anticipated benefits substantially outweigh the potential risks. The risk of hyperkalemia is increased in older patients, those with certain disease states (e.g., renal impairment, diabetes, severe or worsening heart failure, dehydration) or when ARBs are also combined with other agents that increase serum potassium (e.g., nonsteroidal anti-inflammatory drugs, beta-blockers, cyclosporine, heparin, tacrolimus, trimethoprim). Should the benefits outweigh the risks for a particular patient, serum potassium and renal function should be checked prior to initiating therapy and regularly thereafter. Patients and their caregivers should be given counseling on the appropriate levels of potassium and fluid intake, and advised to seek medical attention if they experience signs and symptoms of hyperkalemia (e.g., nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat). Individual product labeling should be consulted for further guidance.

If you are currently receiving treatment with azilsartan, let your doctor know before you take sodium sulfate. Bowel cleansing can cause dehydration and electrolyte abnormalities, and the risk may be increased if you also use azilsartan or other medications that can affect kidney function. In severe cases, dehydration and electrolyte abnormalities can lead to irregular heart rhythm, seizures, and kidney problems. You may need a dose adjustment or special tests to safely use both medications. You should use sodium sulfate exactly as prescribed by your doctor, and drink plenty of clear fluids before, during, and after the cleansing process to keep yourself hydrated. Contact your doctor if you experience signs and symptoms of low electrolyte levels such as weakness, tiredness, drowsiness, dizziness, confusion, tingling, numbness, muscle pain, cramps, nausea, or vomiting. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data